Do not underestimate the power of antibodies - Lessons from adoptive transfer of antibodies against HIV

Vaccine

Volumn 20, Issue SUPPL. 4, 2002, Pages

  Ferrantelli, Flavia ^a   Rasmussen, Robert A ^a   Hofmann Lehmann, Regina ^a   Xu, Weidong ^a   McClure, Harold M ^b   Ruprecht, Ruth M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

AIDS vaccine; Neutralizing antibodies; Passive immunization

Indexed keywords

CD8 ANTIGEN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; B LYMPHOCYTE; CONFERENCE PAPER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIREMIA; VIRUS ISOLATION; VIRUS NEUTRALIZATION; ACUTE DISEASE; ADOPTIVE IMMUNOTHERAPY; CHRONIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; REVIEW; SERODIAGNOSIS;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEUTRALIZATION TESTS;

EID: 0037137509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00389-4     Document Type: Conference Paper

References (36)

1. Koup R.A., Safrit J.T., Cao Y.et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:1994;4650-4655.
2. Ferrantelli F., Ruprecht R.M. Neutralizing monoclonal antibodies against HIV-back in the major leagues? Curr. Opin. Immunol. 14:2002;495-502.
3. Conley A.J., Gorny M.K., Kessler J.A. IIet al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody 447-52D. J. Virol. 68:1994;6994-7000.
4. Verrier F., Nadas A., Gorny M.K., Zolla-Pazner S. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J. Virol. 75:2001;9177-9186.
5. Trkola A., Purtscher M., Muster T.et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type1. J. Virol. 70:1996;1100-1108.
6. Mascola J.R., Louder M.K., VanCott T.C.et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol. 71:1997;7198-7206.
7. Baba T.W., Liska V., Hofmann-Lehmann R.et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200-206.
8. Xu W., Smith-Franklin B.A., Li P.L.et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J. Hum. Virol. 4:2001;55-61.
9. Zwick M.B., Labrijn A.F., Wang M.et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:2001;10892-10905.
10. Zwick M.B., Wang M., Poignard P.et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:2001;12198-12208.
11. Stiegler G., Kunert R., Purtscher M.et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 17:2001;1757-1765.
12. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS, in press.
13. Mascola J.R., Lewis M.G., Stiegler G.et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:1999;4009-4018.
14. Mascola J.R., Stiegler G., VanCott T.C.et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207-210.
15. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A.et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75:2001;7470-7480.
16. Parren P.W., Marx P.A., Hessell A.J.et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian-human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:2001;8340-8347.
17. Li J.T., Halloran M., Lord C.I.et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol. 69:1995;7061-7067.
18. Reimann K.A., Li J.T., Veazey R.et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70:1996;6922-6928.
19. Shibata R., Maldarelli F., Siemon C.et al. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J. Infect. Dis. 176:1997;362-373.
20. Hofmann-Lehmann R., Vlasak J., Rasmussen R.A.et al. Post-natal pre- and post-exposure passive immunization strategies: protection of neonatal macaques against oral-simian immunodeficiency virus challenge. J. Med. Primatol. 31:2002;109-119.
21. Gandhi R.T., Walker B.D. Immunologic control of HIV-1. Annu. Rev. Med. 53:2002;149-172.
22. (+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:1999;991-998.
23. + T-cell-depleted macaques. AIDS. 31:2002;40-60.
24. + lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154:1999;1923-1932.
25. Barouch D.H., Santra S., Schmitz J.E.et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
26. Amara R.R., Villinger F., Altman J.D.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
27. Allen T.M., O'Connor D.H., Jing P.et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407:2000;386-390.
28. Barouch D.H., Kunstman J., Kuroda M.J.et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339.
29. Fazekas de St G., Webster R.G. Disquisitions of Original Antigenic Sin. I. Evidence in man. J. Exp. Med. 124:1966;331-345.
30. Janeway CA, Travers P, Walport M, Capra JD. Immunobiology: The Immune System in Health and Disease. New York, NY: Current Biology Publications; 1999. p. 636.
31. Nara P.L. Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development. Adv. Vet. Med. 41:1999;115-134.
32. Locher C.P., Grant R.M., Collisson E.A.et al. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res. Hum. Retroviruses. 15:1999;1685-1689.
33. Nara P.L., Garrity R. Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine. 16:1998;1780-1787.
34. Rasmussen R.A., Montefiori D.C., Robinson H.L., McClure H.M., Ruprecht R.M. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of Original Antigenic Sin. J. Infect. Dis. 184:2001;1603-1607.
35. McElrath M.J., Corey L., Greenberg P.D.et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. U.S.A. 93:1996;3972-3977.
36. Rasmussen R.A., Hofmann-Lehmann R., Montefiori D.C.et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J. Med. Primatol. 31:2002;40-60.